Overview

Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels

Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The hypothesis of the presented study is: Telmisartan induces an increase of eNOS activity in RBC resulting in an enhanced intravascular NO bioavailability, an ameliorated RBC deformability and a reduction of RBC and platelet aggregation. This could be a potential mechanism of the improvement of microcirculatory disorders, especially in patients with diabetes mellitus and arterial hypertension, treated with Telmisartan.
Phase:
Phase 4
Details
Lead Sponsor:
RWTH Aachen University
Collaborators:
Bayer
CTCA
Heidelberg University
Treatments:
Angiotensin Receptor Antagonists
Telmisartan